Scotiabank restated their outperform rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research report released on Tuesday morning. The brokerage currently has a C$5.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. TD Securities reiterated a speculative buy rating and issued a C$4.50 price objective on shares of ProMetic Life Sciences in a research report on Wednesday, November 16th. Royal Bank Of Canada reiterated an outperform rating on shares of ProMetic Life Sciences in a research report on Thursday, October 13th. CIBC dropped their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Canaccord Genuity boosted their target price on ProMetic Life Sciences from C$4.50 to C$4.75 and gave the stock a buy rating in a research report on Friday, November 18th. Finally, Bloom Burton restated a hold rating on shares of ProMetic Life Sciences in a research report on Thursday, October 13th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Shares of ProMetic Life Sciences (TSE:PLI) opened at 2.46 on Tuesday. ProMetic Life Sciences has a 52 week low of $1.88 and a 52 week high of $3.62. The stock’s market capitalization is $1.53 billion. The company has a 50-day moving average price of $2.81 and a 200 day moving average price of $2.90.

TRADEMARK VIOLATION WARNING: “ProMetic Life Sciences Inc. (PLI) Receives “Outperform” Rating from Scotiabank” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of US & international copyright laws. The correct version of this article can be viewed at http://www.dailypolitical.com/2016/11/30/prometic-life-sciences-inc-pli-receives-outperform-rating-from-scotiabank.html.

About ProMetic Life Sciences

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.